PD-L1 x CD28 TRACIr (JANX009)

Our PDL1-TRACIr drug candidate is designed to bind to immunosuppressive PD-L1 on tumor cells as well as to the CD28 costimulatory receptor on T cells. The CD28 costimulatory domain is masked to prevent off tumor activation of T cells.

Janux is developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific drug candidate (JANX009) that targets both the programmed death-ligand 1 (PD-L1) receptor as well as the co-stimulatory CD28 receptor on T cells.

Our single-masked PD-L1 x CD28 costimulatory bispecific is designed to be unmasked only in the tumor microenvironment and to conditionally agonize CD28 only in the presence of PD-L1, which is often overexpressed by tumors to avoid T cell mediated killing.

Our bispecific molecule is designed to bind to immunosuppressive PD-L1 on tumor cells as well as to the CD28 costimulatory receptor on T cells.

unique-immunotherapies-cc
Preclinically, we have shown that the use of this bispecific led to potent T cell-directed tumor cell killing in cell assays in which a checkpoint inhibitor was ineffective. In addition, our costimulatory program enhanced the potency of tumor cell killing when combined with a T cell engager.

We have a range of immuno-oncology programs currently in development.